Once Daily 3TC, Efavirenz and ddI for HIV Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00214435 |
Recruitment Status
: Unknown
Verified September 2005 by 407 Doctors.
Recruitment status was: Recruiting
First Posted
: September 22, 2005
Last Update Posted
: October 25, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infection AIDS | Drug: once daily minimum 3-drug regimen of anti-retroviral medications | Phase 4 |
Rationale: ‘TEddI’ will enable a once-daily treatment strategy to be studied and provide information on effectiveness, patient adherence and quality of life and the tolerability of such regimens.
Hypothesis: The study hypothesis is that an antiretroviral regimen comprising of three agents taken once daily will have higher levels of adherence than a regimen requiring more frequent dosing.
Primary objective: To determine over 24 weeks the levels of adherence in two groups of HIV-infected subjects randomised to receive either a once daily minimum 3-drug regimen or to continue a minimum 3-drug regimen requiring more frequent dosing.
Secondary objectives: The secondary objectives of the study will include:
- To estimate the proportion of patients with treatment failure where treatment failure is defined as:
- HIV-1 RNA viral load of >400 copies/ml on two consecutive occasions more than one month apart, OR
- Discontinuation of treatment for any reason (where subsequent therapy does not comply with the study regimen change guidelines outlined in section 3.3.3)
- Proportion of patients with plasma HIV-RNA less than 50 copies/ml (using an ultrasensitive assay) at 24 and 48 weeks
- Change from baseline in CD4 cell count at 24 and 48 weeks
- Changes from baseline in subjects’ quality of life at 24 and 48 weeks
- Changes from baseline based on DASS 21 scores at 24 and 48 weeks
- Incidence and severity of adverse events and abnormal laboratory values (grade 3 & 4) at 24 and 48 weeks
- Proportion of patients remaining on assigned treatment Study Design This is a randomised, open-label, multi-centre, prospective, 48-week study comparing a 3 (or more) drug once-daily antiretroviral regimen with any 3 (or more) drug regimen in which at least 1 drug must be taken at least twice daily.
One hundred and twenty (120) subjects will be recruited and randomised in a 1:1 ratio to one of two open-label treatment regimens and will continue to receive randomised treatment until week 24:
Arm 1: (Once daily arm) commence treatment with a once-a-day combination of licensed antiviral medications (such as EFV/ddI/3TC, EFV/3TC/TDF or ATV/3TC/TDF).
Arm 2: (Continuation arm) continue current ART (minimum 3-drugs) dosed twice daily or more frequently
Following week 24, patients will have the option to continue randomised treatment for a further 24 weeks or switch to the once daily treatment arm. In all cases, patients will be followed up for 48 weeks from the baseline visit.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily |
Study Start Date : | May 2004 |

- - levels of adherence
- - proportion of patients with treatment failure where treatment failure is defined
- - HIV-1 RNA viral load of >400 copies/ml on two consecutive occasions more than one month apart, OR discontinuation of treatment for any reason (where subsequent therapy does not comply with the study regimen change guidelines outlined in section 3.3.3)
- - proportion of patients with plasma HIV-RNA less than 50 copies/ml (using an ultrasensitive assay) at 24 and 48 weeks
- - change from baseline in CD4 cell count at 24 and 48 weeks
- - changes from baseline in subjects’ quality of life at 24 and 48 weeks
- - changes from baseline based on DASS 21 scores at 24 and 48 weeks
- - incidence and severity of adverse events and abnormal
- - laboratory values (grade 3 & 4) at 24 and 48 weeks
- - proportion of patients remaining on assigned treatment

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aged 18 years or more with laboratory evidence of HIV-1 infection
- ability to understand and provide written informed consent to participate in the study
- stable on current ART regimen for at least 3 months prior to screening.
- plasma HIV-RNA less than 400 copies/ml at the screening visit.
- women of child bearing potential must have a negative serum or urine β-HCG pregnancy test within 14 days prior to week -4 (assessment of study eligibility)
Exclusion Criteria:
- virological failure of a proposed Once daily arm medication
- a serious medical condition which may compromise the subject’s safety, including an active AIDS-defining condition within the previous 6 months
- known toxicities to any of the proposed Once daily arm medications
- laboratory abnormalities at screening:
- serum creatinine greater than twice the upper limit of normal (2 x upper limit of normal (ULN))
- AST, ALT or alkaline phosphatase greater than 5 times the ULN
- lactate greater than 2.5 x ULN
- haemoglobin less than 9.5 g/dL
- women who are pregnant or breast-feeding or who, if of child-bearing potential, are not willing to use adequate contraception (including barrier contraception)
- patients who in the investigator’s opinion are unlikely to complete the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214435
Contact: David A Baker, MB ChB | 02 9332 2531 | db@407.com.au | |
Contact: Robyn Vale, RN | 02 9332 2531 |
Australia, New South Wales | |
407 Doctors | Recruiting |
Sydney, New South Wales, Australia, 2010 | |
Contact: David A Baker, MB ChB 02 9332 2531 db@407.com.au | |
Principal Investigator: David A Baker, MB ChB |
Principal Investigator: | David A Baker, MB ChB | 407 Doctors |
ClinicalTrials.gov Identifier: | NCT00214435 History of Changes |
Other Study ID Numbers: |
TEddI |
First Posted: | September 22, 2005 Key Record Dates |
Last Update Posted: | October 25, 2005 |
Last Verified: | September 2005 |
Keywords provided by 407 Doctors:
HIV infection AIDS Adherence MEMS caps Treatment Experienced |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Efavirenz |
Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers |